



ISSN: 1741-5993 (Print) 1741-6000 (Online) Journal homepage: https://www.tandfonline.com/loi/gsrp20

One-pot, solvent-free facile stereoselective synthesis of rhodanine-furan hybrids from renewable resources

Leila Sabahi-Agabager & Farough Nasiri

To cite this article: Leila Sabahi-Agabager & Farough Nasiri (2019): One-pot, solvent-free facile stereoselective synthesis of rhodanine-furan hybrids from renewable resources, Journal of Sulfur Chemistry, DOI: 10.1080/17415993.2019.1702196

To link to this article: <u>https://doi.org/10.1080/17415993.2019.1702196</u>

|--|

View supplementary material 🖸



Published online: 15 Dec 2019.

_	
r	
-	_

Submit your article to this journal 🗹



View related articles



View Crossmark data 🗹



Check for updates

One-pot, solvent-free facile stereoselective synthesis of rhodanine–furan hybrids from renewable resources

Leila Sabahi-Agabager and Farough Nasiri

Department of Applied Chemistry, University of Mohaghegh Ardabili, Ardabil, Iran

ABSTRACT

In this study, a one-pot, solvent-free stereoselective reaction was started between primary amines, carbon disulfide, ethyl bromoacetate, and furan derivatives derived from sugars at room temperature, which was completed within 10 min to produce rhodanine–furan hybrid molecules in good to high yields. The presence of the chloromethyl group in products derived from chloromethylfurfural (CMF) made it possible for the substitution of other functional groups such as amine group.



ARTICLE HISTORY

Received 10 November 2019 Accepted 3 December 2019

KEYWORDS

5-arylidene rhodanines; furans; solvent-free reaction; multicomponent reactions (MCRs); biomass

Introduction

To optimize the biological activity of synthetic molecules, it is essential to have a different design of the molecules. The synthesis of hybrid molecules is a way to achieve this goal, which has been further considered in recent decades to improve the biological activity of synthetic compounds [1]. Sugars represent a renewable source for the production of furan derivatives. The furan scaffold consists of several bioactive natural products such as furanolactones, furano-flavonoids, and furanocoumarins. The furan

(b) This article makes reference to supplementary material available on the publisher's website at https://doi.org/10.1080/17415993.2019.1702196

© 2019 Informa UK Limited, trading as Taylor & Francis Group

CONTACT Farough Nasiri an asiri@uma.ac.ir Department of Applied Chemistry, University of Mohaghegh Ardabili, P.O. Box 56199-11367, Ardabil, Iran.

2 👄 L. SABAHI-AGABAGER AND F. NASIRI

derivatives have been reported to show more than 18 various pharmacologically activities [2]. High remedial properties of furan-containing drugs have motivated organic chemists to synthesize various furan derivatives. On the other hand, the arylidene rhodanine-based compounds are considerable heterocyclic molecules with diverse pharmacological activities such as anticancer [3], anti-bacterial [4], anti-diabetic [5], antifungal [6], and anti-HIV [7]. These molecules also inhibit numerous targets such as aldose reductase [8], hepatitis C virus (HCV) NS3 protease [9], PRL-3 [10], and UDPN-acetylmuramate/L-alanine ligase [11]. Recently, rhodanine-based molecule supported on nanomagnetic particles has also been used to remove heavy metal contamination [12] or used as a catalyst for organic transformations [13,14].

Due to the above observations, we were interested in the synthesis of hybrid molecules containing furan and rhodanine moieties (5-arylidene rhodanines) by the reaction of furanaldehydes (furfural and other furanaldehyde derivatives obtained from sugar), carbon disulfide, ethylbromoacetate, and primary amines. Among most of the reported synthesis methods used to generate arylidene rhodanines, the Knoevenagel condensation between rhodanine units and aldehydes has been done frequently through a separate step in the presence of an appropriate base [15-26]. Recently, a few reports have been published regarding the four-component synthesis of arylidene rhodanines. In these reports, ultrasonic or microwave conditions have been used to facilitate the reaction [27,28] or the reaction has been performed in ionic liquid [29] and to the best of our knowledge, there is no report about the one-pot solvent-free synthesis of arylidene rhodanines. To develop easy and green synthesis of arylidene rhodanines without isolation of reaction intermediates or purification step, and in continuation of our research on one-pot solvent-free synthesis of heterocyclic compounds [30-33], this study was conducted to report a onepot solvent-free reaction between primary amines 1, carbon disulfide, ethyl bromoacetate, and renewable furan derivatives 2 in the presence of a catalytic amount of triethylamine to produce rhodamine-furan hybrids 3 in good to high yields within 10 minutes.

Results and discussion

The one-pot reaction between phenethyl amine 1a, carbon disulfide, ethyl bromoacetate, and chloromethylfurfural (CMF) 2a was selected as a model reaction to produce rhodanine-furan hybrid 3a (Scheme 1). At first, to achieve an efficient procedure, the one-pot methods reported in the literature were used for the synthesis of the compound 3a. As illustrated in Scheme 2, when the reaction was carried out by the Azizi's method [27] in PEG and the presence of 300 mol% of KOH and ultrasonic condition, the reaction yield was negligible. Also, when the reaction was performed according to the Mermer's method [28] in water and the presence of 300 mol% of triethylamine and ultrasonic condition, the reaction yield was only 20%. The deletion of ultrasonic condition in the recent reaction [28] reduced reaction yield to 14%. When the reaction was carried out in solvent-free condition with an equimolar ratio of reactant and in presence of 20 mol% of triethylamine, **3a** created with a yield of 33% within 10 min (Table 1, entry 1). The increase in the amount of triethylamine did not influence on yield of **3a** (Table 1, entries 1, 2). In this reaction, bromoethylacetate was added to the mixture of phenethylamine and CS₂, and the reaction mixture was stirred by a glass rod for 2 minutes. Then, CMF and triethylamine were added respectively to the mixture and mixing was continued, and progress of the reaction



Scheme 1. One-pot reaction between phenetyl amine, CS₂, CMF, and ethyl bromoacetate.



Scheme 2. Synthesis of 3a through a number of methods reported in the literature.

	Mola					
Entry	Phenethylamine	CS ₂	Ethylbromoacetate	Et_3N	Time	Yield% of 3a
1	1	1	1	0.2	10 min	33
2	1	1	1	0.4	10 min	33
3	1	1	1	0.2 ^a	1 day	Trace
4 ^b	1	1	1	0.2	10 min	_c
5	2	2	2	0.4	10 min	40
6	2.5	2.5	2.5	0.5	10 min	63
7	3	3	3	0.6	10 min	62

 Table 1. Optimization of the reaction conditions for the synthesis of compound 3a.

^aWhen triethylamine was added to the reaction mixture before adding CMF.

^bThe reaction was carried out at 60°C.

^cThe reaction afforded a complex oily mixture.

was monitored by the TLC. After 8 min, the reaction was completed. The product was easily separated by adding ethanol to the reaction mixture. In this reaction, the progress of the reaction was significantly influenced by the order of the reactant addition. When triethylamine was added to the reaction mixture before adding CMF, the reaction yield was negligible after 24 hours (Table 1, entry 3). Also, this reaction was sensitive to temperature, and when the reaction was carried out at 60°C, the reaction afford a complex mixture 4 🛭 😔 🛛 L. SABAHI-AGABAGER AND F. NASIRI



Scheme 3. One-pot, solvent-free stereoselective reaction between phenetyl amine, CS₂, CMF, and ethyl bromoacetate.

(Table 1, entry 4). To obtain the optimum reaction conditions in terms of reactant amount, the model reaction was checked in the presence of different ratios of reactant relative to CMF. As shown in Table 1, reasonable reaction yield was gained when the reaction was carried out using 2.5 times of reactant and 50 mol% of trimethylamine relative to CMF at room temperature (Table 1, entries 5–7).

As shown in Scheme 3, two possible stereoisomers (3a and 3a') can be formed in this reaction. These isomers can be detected from each other based on the chemical shift of olefinic hydrogen in the ¹H NMR. In the Z-form (3a), methine proton is located in the deshielding region of adjacent carbonyl group. This proton appears at about 7.0-8.0 ppm, while in the *E*-form (3a'), this proton should appear at about less than 6.5 ppm [15]. The¹H NMR chemical shift of methine proton in products of this reaction appears in a range of 7.4–7.6 ppm, showing that only Z isomer has been produced. The reason for the formation of **3** in Z-form is due to the high degree of thermodynamic stability of Z-form in this compound [3]. Structures of the produced 5-arylidene rhodanines derivatives were determined based on their IR, ¹H NMR, ¹³C NMR, and mass spectroscopic data. For example, the ¹H NMR spectrum of **3c** showed three singlets ($\delta = 2.32, 4.63, \text{ and } 5.28 \text{ ppm}$) related to the methyl, CH₂N, and CH₂Cl protons, respectively. Protons of the furan ring showed two doublets ($\delta = 6.55$ and 6.78 ppm, ${}^{3}J_{HH} = 3.5$ Hz). The methine proton of **3c** appeared as a singlet at $\delta = 7.44$ ppm, revealing that the compound **3c** is produced as only Z-form [15]. Also, aromatic protons of **3c** produced two doublets at δ = 7.13 and δ = 7.36 ppm $({}^{3}J_{\rm HH} = 7.7 \, {\rm Hz})$. Also, the ${}^{13}{\rm C}$ NMR spectrum of **3c** showed 15 distinct signals confirming the proposed structure. Mass spectrum of 3c illustrated a molecular ion peak at the expected m/z value, *i.e.* 363 (Table 2).

To generalize the reported method to other aldehydes, we examined this procedure for benzaldehyde. The yield of desired product was about 60%, indicating that this method can be extended to other aldehydes as well.

A proposed mechanism for this reaction is shown in Scheme 4. The reaction proceeds through an initial addition of the amine 1 to carbon disulfide to afford zwitterionic intermediate I [34] which then reacts with ethyl bromoacetate with the loss of one HBr molecule to convert it into the intermediate II. Intermediate II undergoes an intramolecular cyclization to produce rhodanine III with diverse R^1 groups with loss of the ethanol molecule. Condensation of rhodanine III with furan derivatives 2 in the presence of NEt₃ gave the rhodanine–furan hybrids 3.

Chlorine atom in the compounds 3a-3d has potential for substitution with various functional groups. The amino group is one of the most important functional group in

bioactive compounds, which by converting to ammonium salts, makes it possible to solubilize organic compounds in an aqueous medium. Compound 3a easily reacted with hexamethylenetetramine to produce intermediate 4 (Scheme 5) which was converted to its





6 🕒 L. SABAHI-AGABAGER AND F. NASIRI

Table 2. Continued.



^a Isolated yields.

ammonium salt of rhodanine–furan hybrid 5 by treating with acidic ethanol at reflux condition [35]. The ¹H NMR spectrum of 5 showed a triplet ($\delta = 2.95$ ppm, ³J_{HH} = 9.0 Hz) related to CH₂-Ar protons, and the two methylene protons of CH₂-N moieties overlapped with each other at $\delta = 4.20-4.24$ ppm. One of the two protons of the furan ring showed a doublet at δ 6.86 ppm with ³J_{HH} = 3.5 Hz, and other proton of the furan ring overlapped with aromatic proton signals at $\delta = 7.19-7.30$ ppm. The methine proton appeared as a singlet at $\delta = 7.59$ ppm. The NH₃⁺ protons of 5 resulted as a broad singlet at δ 8.87 ppm. This resonance disappeared after the addition of D₂O to the DMSO solution of 5. In addition, the ¹³C NMR spectrum of 5 showed 15 distinct signals confirming the proposed



Scheme 4. A proposed mechanism for the formation of rhodanine–furan hybrids through the reaction between primary amines, CS₂, furan derivatives, and ethyl bromoacetate.



Scheme 5. Synthesis of ammonium salt of rhodanine–furan hybrid 5.

structure. Mass spectrum of 5 displayed a (M⁺-HCl) peak at m/z 344, corresponding with the proposed structure.

Conclusion

The present one-pot solvent-free and stereoselective reaction between primary amines, carbon disulfide, ethylbromoacetate, and furfural derivatives derived from sugars provided a novel series of furan-rhodanine hybrids in good to high yields within 10 minutes. The presence of the chloromethyl group in products derived from CMF made it possible for the substitution of other functional groups such as amine group. Also, the simplicity of the present procedure and facility of the product isolation made it an interesting alternative to more complex methods.

Experimental section

General information

Thin layer chromatography was carried out using commercially available Merck F254 aluminum backed silica plates and Silica gel (60 meshes) was used for column chromatography. Melting points (un-corrected) were measured with a Stuart SMP-3 apparatus. IR spectra of products were measured with an FTIR Perkin Elmer RXI. NMR spectra were

recorded with a Bruker DRX-250 AVANCE instrument (250.1 MHz for ¹H and 62.5 MHz for¹³C) or INOVA-500 (500 MHz for ¹H and 125 MHz for ¹³C) with CDCl₃ or DMSO as the solvent. Chemical shifts are given in ppm (δ) relative to internal TMS, and coupling constants (*J*) are reported in Hertz (Hz). 5-(Chloromethyl)furfural was prepared from powdered sugar according to the published procedure [36]. 5-(Hydroxymethyl)furfural was prepared from fructose according to the published procedure [37]. Other starting materials and solvents were obtained from Merck (Germany) and were used without further purification.

General procedure for the preparation of 3-alkyl-5-((5-(hydroxymethyl)furan-2-yl) methylene)-2-thioxothiazolidin-4-one (**3a-j**)

To a mixture of amine (2.5 mmol) and CS_2 (2.5 mmol) was added ethyl bromoacetate (2.5 mmol). The contents were admixed by glass rod at room temperature for 2 minutes. Then furanaldehyde derivative (1 mmol) and NEt₃ (0.5 mmol) were added to the mixture and mixing was continued for 8 min. After the reaction completed, ethanol (when the aldehyde reactant was CMF) or water (when the aldehyde reactant was HMF or furfural) was added to the reaction mixture and the product was collected by filtration.

(Z)-5-((5-(Chloromethyl)furan-2-yl)methylene)-3-phenethyl-2-thioxothiazolidin-4-one (3a)

Yellow powder; mp: 144–147°C; 0.229 g, yield: 63%. IR (KBr) (υ_{max}/cm^{-1}) : 3036, 1699, 1613, 1352, 1329, 1261, 1165. Ms: m/z (%) = 363 (M^{+,} 32), 328 (18), 259 (39), 172 (61), 137 (100), 83 (32). ¹H NMR (250 MHz, CDCl₃): δ ppm 3.00 (t, 2H, ${}^{3}J_{\rm HH} = 8.0$ Hz, CH_2 Ar), 4.32 (t, 2H, ${}^{3}J_{\rm HH} = 8.0$ Hz, NCH₂), 4.63 (s, 2H, CH_2 Cl), 6.55 (d, 1H, ${}^{3}J_{\rm HH} = 3.5$ Hz, $CH_{\rm Furan}$), 6.78 (d, 1H, ${}^{3}J_{\rm HH} = 3.5$ Hz, $CH_{\rm Furan}$), 7.29–7.40 (m, 5H, Ar), 7.43 (s, 1H, = CH); ¹³C NMR (62.5 MHz, CDCl₃): δ ppm 33.0 (CH₂Ph), 36.9 (CH₂Cl), 45.6 (CH₂N), 112.9 and 117.6 (2CH_{Furan}), 119.1 (CH = C_{Rhodanin}), 121 (CH = C_{Rhodanin}), 126.8 (CH), 128.6 (2CH), 128.9 (2CH), 137.5 (C_{Ar}), 150.6 and 154.7 (2C_{Furan}), 167.2 (C = O) and 194.1 (C = S).

(Z)-3-Benzyl-5-((5-(chloromethyl)furan-2-yl)methylene)-2-thioxothiazolidin-4 -one (3b)

Yellow powder; mp: 139–143°C; 0.226 g, yield: 65%. IR (KBr) (υ_{max}/cm^{-1}) : 3035, 1702, 1610, 1301, 1187, 695, 529. MS (m/z, %): 349 (M⁺, 53), 314 (25), 172 (58), 137 (100), 91 (56), 65 (25). ¹H NMR (500.1 MHz, CDCl₃): δ ppm 4.63 (s, 2H, *CH*₂N), 5.31 (s, 2H, *CH*₂Cl), 6.55 (d, 1H, ³*J*_{HH} = 3.5 Hz, *CH*_{Furan}), 6.78 (d, 1H, ³*J*_{HH} = 3.5 Hz, *CH*_{Furan}), 7.28–7.34 (m, 3H, Ar), 7.44 (s, 1H, =*CH*), 7.45–7.48 (m, 2H, Ar); ¹³C NMR (125.7 MHz, CDCl₃): δ ppm 37.0 (*CH*₂Cl), 47.6 (*CH*₂N), 113.1 (*CH*_{Furan}), 117.9 (*CH*_{Furan}), 119.3 (*CH* = *C*_{Rhodanin}), 122.1 (*CH* = *C*_{Rhodanin}), 128.2 (*CH*), 128.7 (2*CH*), 129.0 (2*CH*), 135.0 (*C*_{Ar}), 150.7 (*C*_{Furan}), 154.9 (*C*_{Furan}), 167.6 (*C* = O) and 194.3 (*C* = S).

(Z)-3-(4-Methyl-benzyl)-5-((5-(chloromethyl)furan-2-yl)methylene)-2-thioxothiaz olidin-4-one (3c)

Yellow powder; mp: 158–160°C; 0.214 g, yield: 59%. IR (KBr) (v_{max}/cm^{-1}) : 1702, 1609, 1341, 1306, 1184, 1044. MS (*m*/*z*, %): 363 (M⁺, 53), 329 (21), 172 (31), 137 (53), 105 (100), 63 (61). ¹H NMR (500.1 MHz, CDCl₃): δ ppm 2.32 (s, 3H, CH₃), 4.63 (s, 2H, NCH₂), 5.28 (s, 2H, CH₂Cl), 6.55 (d, 1H, ³*J*_{HH} = 3.5 Hz, CH_{Furan}), 6.78 (d, 1H, ³*J*_{HH} = 3.5 Hz,

 CH_{Furan}), 7.13 (d, 2H, ${}^{3}J_{HH} = 7.7$ Hz, Ar), 7.36 (d, 2H, ${}^{3}J_{HH} = 7.7$ Hz, Ar), 7.43 (s, 1H, = CH); ${}^{13}C$ NMR (125.7 MHz, CDCl₃): δ ppm 21.3 (CH₃), 37.0 (CH₂Cl), 47.4 (CH₂N), 113.1 (CH_{Furan}), 117.8 (CH_{Furan}), 119.3 (CH = C_{Rhodanin}), 122.2 (CH = C_{Rhodanin}), 129.0 (2CH), 129.4 (2CH), 132.0 (C), 138.0 (C), 150.7 (C_{Furan}), 154.9 (C_{Furan}), 167.6 (C = O) and 194.3 (C = S).

(Z)-5-((5-(Chloromethyl)furan-2-yl)methylene)-3-(2-methoxyethyl)-2-thioxothiaz olidin-4-one (3d)

Yellow powder; mp: 134–140°C; 0.200 g, yield: 63%. IR (KBr) (υ_{max}/cm^{-1}) : 1710, 1608, 1327, 1221, 1126, 1105. MS (m/z, %): 317 (M⁺, 15), 282 (16), 258.9 (24), 172 (39), 137 (100), 63 (25). ¹H NMR (500.1 MHz, CDCl₃): δ ppm 3.36 (s, 3H, CH₃O), 3.70 (t, 2H, ³J_{HH} = 5.8 Hz, NCH₂), 4.35 (t, 2H, ³J_{HH} = 5.8 Hz, OCH₂), 4.63 (s, 2H, CH₂Cl), 6.56 (d, 1H, ³J_{HH} = 3.6 Hz, CH_{Furan}), 6.78 (d, 1H, ³J_{HH} = 3.6 Hz, CH_{Furan}), 7. 44 (s, 1H, =CH); ¹³C NMR (125.7 MHz, CDCl₃): δ ppm 37.0 (CH₂Cl), 43.6 (CH₂N), 59.0 (CH₃O), 68.4 (CH₂O), 113.1(CH_{Furan}), 117.7 (CH_{Furan}), 119.2 (CH = C_{Rhodanin}), 121.9 (CH = C_{Rhodanin}), 150.6 (C_{Furan}), 154.7 (C_{Furan}), 167.5 (C = O) and 194.5 (C = S).

(Z)-5-((5-(Hydroxymethyl)furan-2-yl)methylene)-3-phenethyl-2-thioxothiazolidin -4-one (3e)

Yellow powder; mp: 108–109°C; 0.259 g, yield: 75%. IR (KBr) (v_{max}/cm^{-1}) : 3422, 1700, 1607, 1328, 1256, 1166, 1023, 805, 697. MS (m/z, %): 345 (M⁺, 34), 241 (37), 154 (100). ¹H NMR (500.1 MHz, CDCl₃): δ ppm 1.76 (s, 1H, OH), 3.01 (t, 2H, ³J_{HH} = 10.0 Hz, CH₂-Ar), 4.33 (t, 2H, ³J_{HH} = 10.0 Hz, N–CH₂), 4.73 (s, 2H, CH₂-OH), 6.51 (d, 1H, ³J_{HH} = 3.5 Hz, CH_{Furan}), 6. 81 (d, 1H, ³J_{HH} = 3.5 Hz, CH_{Furan}), 7.23–7.35 (m, 5H, Ar), 7. 42 (s, 1H, = CH);¹³C NMR (125.7 MHz, CDCl₃): δ ppm 32.9 (CH₂Ph), 45.5 (CH₂-N), 57.6 (CH₂-OH), 111.1 (CH_{Furan}), 118.0 (CH_{Furan}), 119.5 (CH = C_{Rhodanin}), 120.6 (CH = C_{Rhodanin}), 126.6 (CH), 128.5 (2CH), 128.8 (2CH), 137.4 (C_{Ar}), 149.7 (C_{Furan}), 159.0 (C_{Furan}), 167.1 (C=O) and 194.0 (C=S).

(Z) - 3 - Benzyl - 5 - ((5 - (hydroxymethyl) furan - 2 - yl) methylene) - 2 - thioxothiazolidin - 4 - one(3f)

Yellow powder; mp: 150–152°C; 0.148 g, yield: 45%. IR (KBr) (υ_{max}/cm^{-1}) : 3422, 1702, 1607, 1302, 1190, 1007. MS (m/z, %): 329 (M⁺-2, 4), 311 (11), 134 (24), 91 (45), 63 (100).¹H NMR (500.1 MHz, CDCl₃): δ ppm 2.25 (s, 1H, OH), 4.69 (s, 2H, CH₂N), 5.30 (s, 2H, CH₂OH), 6.45 (d, 1H, ³J_{HH} = 3.5 Hz, CH_{Furan}), 6.78 (d, 1H, ³J_{HH} = 3.5 Hz, CH_{Furan}), 7.28–7.34 (m, 3H, Ar) 7. 44 (s, 1H, =CH), 7.45–7.47 (m, 2H, Ar);¹³C NMR (125.7 MHz, CDCl₃): δ ppm 47.4 (CH₂N), 57.6 (CH₂OH), 111.2 (CH_{Furan}), 118.3 (CH_{Furan}), 119.8 (CH = C_{Rhodanin}), 120.6 (CH = C_{Rhodanlin}), 128.1 (CH), 128.6 (2CH), 128.9 (2CH), 134.9 (C_{Ar}), 149.8 (C_{Furan}), 159.4 (C_{Furan}), 167.6 (C = O) and 194.2 (C = S).

(Z)-3-(4-Methyl-benzyl)-5-((5-(hydroxymethyl)furan-2-yl)methylene)-2-thioxothi azolidin-4-one (3g)

Yellow powder; mp: 177–180°C; 0.207 g, yield: 60%. IR (KBr) (v_{max}/cm^{-1}): 3424, 1699, 1608, 1342, 1305, 1188, 1022. MS (m/z, %): 345 (M⁺, 29), 154 (44), 105 (43), 63 (100). ¹H NMR (500.1 MHz, CDCl₃): δ ppm 2.31 (s, 3H, CH₃), 3.96 (s, 1H, OH), 4.70 (s, 2H, NCH₂), 5.26 (s, 2H, CH₂OH), 6.47 (d, 1H, ³J_{HH} = 3.5 Hz, CH_{Furan}), 6.77 (d, 1H, ³J_{HH} = 3.5 Hz, CH_{Furan}), 7.12 (d, 2H, J_{HH} = 7.8, Ar), 7.36 (d, 2H, J_{HH} = 8.0, Ar), 7. 41 (s, 1H, = CH); ¹³C NMR (125.7 MHz, CDCl₃): δ ppm 21.2 (CH₃), 47.2 (CH₂N), 57.7 (CH₂OH),

10 🕒 L. SABAHI-AGABAGER AND F. NASIRI

111.2(CH_{Furan}), 118.2 (CH_{Furan}), 119.6 ($CH = C_{Rhodanin}$), 120.8 ($CH = C_{Rhodanin}$), 129.0 (2CH), 129.2 (2CH), 131.9. (C), 137.9 (C), 149.8 (C_{Furan}), 159.2 (C_{Furan}), 167.6 (C = O), 194.2 (C = S).

(Z)-5-((5-(Hydroxymethyl)furan-2-yl) methylene)-3-(2-methoxyethyl)-2-thioxothi azolidin-4-one (3h)

Yellow powder; mp: 94–95°C; 0.144 g, yield: 48%. IR (KBr) (ν_{max}/cm^{-1}): 3423, 1705, 1606, 1340, 1328, 1219, 1187, 1163, 1020. MS (m/z, %): 299 (M⁺, 20), 241 (25), 154 (54), 137 (21), 78 (91), 63 (100). ¹H NMR (500.1 MHz, CDCl₃): δ ppm 2.42 (s, 1H, OH), 3.35 (s, 3H, CH₃O), 3.69 (t, 2H, ³ J_{HH} = 5.8 Hz, NCH₂), 4.32 (t, 2H, ³ J_{HH} = 5.8 Hz, OCH₂), 4.69 (s, 2H, CH₂OH), 6.48 (d, 1H, ³ J_{HH} = 3.5 Hz, CH_{Furan}), 6.77 (d, 1H, ³ J_{HH} = 3.5 Hz, CH_{Furan}), 7. 38 (s, 1H, = CH);¹³C NMR (125.7 MHz, CDCl₃): δ ppm 43.4 (CH₂-N), 57.6 (CH₂-OH), 58.9 (CH₃-O), 68.3 (CH₂-O), 111.2(CH_{Furan}), 118.3 (CH_{Furan}), 119.7 (CH = C_{Rhodanin}), 120.5 (CH = C_{Rhodanin}), 149.8 (C_{Furan}), 159.5 (C_{Furan}), 167.6 (C = O) and 194.6 (C = S).

(Z)-5-((Furan-2-yl)methylene)-3-phenethyl-2-thioxothiazolidin-4-one (3i) Yellow powder; 0.202 g, yield: 64%, mp: 151–152°C [27].

(Z)-3-Benzyl-5-((furan-2-yl)methylene)-2-thioxothiazolidin-4-one (3j)

Yellow powder; 0.172 g, yield: 57%, mp: 140–142°C [29].

Procedure for the preparation of hydrochloride salt of (Z)-5-((5-(aminomethyl)furan-2-yl)methylene)-3-phenethyl-2-thioxothiazolidin-4-one (5)

To a boiling solution of **3a** (364 mg, 1 mmol) in chloroform (6 mL) was added hexamethylenetetramine (196 mg, 1.4 mmol), and the reaction mixture was heated for 4 h under reflux condition. The obtained hexamethylenetetraammonium salt was filtered and dissolved in 4 mL ethanol. Then concentrated HCl (10.0 equiv.) was added to the reaction mixture and the mixture was heated at reflux condition. After 2 hours, compound 5 participate as a yellow powder. Mp: 209–210°C (decomposition); 0.141 g, yield: 37%. IR (KBr) (v_{max}/cm^{-1}): 2864 (br), 1682, 1599, 1329, 1179. MS (m/z, %): 344 (M⁺-36, 81), 240 (48), 153 (100), 96 (52).¹H NMR (500.1 MHz, DMSO): δ ppm 2.95 (t, 2H, ³J_{HH} = 9.0 Hz, CH₂Ar), 4.20–4.24 (m, 4H, NCH₂), 6.86 (d, 1H, ³J_{HH} = 3.5 Hz, CH_{Furan}), 7.19–7.22 (m, 4H, CH_{Furan} and Ar), 7.27–7.30 (m, 2H, Ar), 7.59 (s, 1H, =CH), 8.87 (bs, 3H, NH₃ exchange with D₂O). ¹³C NMR (125.7 MHz, DMSO): δ ppm 32.2 (CH₂Ph), 35.2 (CH₂N), 45.3 (CH₂NH₃), 114.2 (CH_{Furan}), 118.4 (CH_{Furan}), 119.8 (CH = C_{Rhodanin}), 121.4 (CH = C_{Rhodanin}), 126.7 (CH), 128.6 (2CH), 128.7 (2CH), 137.6 (C_{Ar}), 149.7 (C_{Furan}), 153.4 (C_{Furan}), 166.5 (C = O) and 194.4 (C = S).

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

This research was supported by the Iran National Science Foundation (INSF) under grant No. 96004838.

Supporting information

¹H NMR,¹³C NMR, and Mass spectra of all new compounds associated with this article can be found in the online version.

References

- Mishra S, Singh P. Hybrid molecules: the privileged scaffolds for various pharmaceuticals. Eur J Med Chem. 2016;124:500–536.
- [2] Banerjee R, Kumar H, Banerjee M. Medicinal significance of furan derivatives: a review. Int J Rev Life Sci. 2012;2:7–16.
- [3] Mandal SP, Garg A, Sahetya SS, et al. Novel rhodanines with anticancer activity: design, synthesis and CoMSIA study. RSC Adv. 2016;6:58641–58653.
- [4] Heerding DA, Christmann LT, Clark TJ, et al. New benzylidenethiazolidinediones as antibacterial agents. Bioorg Med Chem Lett. 2003;13:3771–3773.
- [5] Momose Y, Meguro K, Ikeda H, et al. Studies on antidiabetic agents. X. synthesis and biological activities of pioglitazone and related compounds. Chem Pharm Bull. 1991;39:1440–1445.
- [6] Sortino M, Delgado P, Juárez S, et al. Synthesis and antifungal activity of (Z)-5-arylidene rhodanines. Bioorg Med Chem. 2007;15:484–494.
- [7] Tintori C, Iovenitti G, Ceresola ER, et al. Rhodanine derivatives as potent anti-HIV and anti-HSV microbicides. PLoS One. 2018;13:e0198478.
- [8] Maccari R, Del Corso A, Giglio M, et al. In vitro evaluation of 5-arylidene-2-thioxo-4-thiazolidinones active as aldose reductase inhibitors. Bioorg Med Chem Lett. 2011;21:200–203.
- [9] Sing WT, Lee CL, Yeo SL, et al. Arylalkylidene rhodanine with bulky and hydrophobic functional group as selective HCV NS3 protease inhibitor. Bioorg Med Chem Lett. 2001;11:91–94.
- [10] Ahn JH, Kim SJ, Park WS, et al. Synthesis and biological evaluation of rhodanine derivatives as PRL-3 inhibitors. Bioorg Med Chem Lett. 2006;16:2996–2999.
- [11] Sim MM, Ng SB, Buss AD, et al. Benzylidene rhodanines as novel inhibitors of UDP-N-acetylmuramate/L-alanine ligase. Bioorg Med Chem Lett. 2002;12:697–699.
- [12] Rahmaninia A, Mansoori Y, Nasiri F. Surface-initiated atom transfer radical polymerization of a new rhodanine-based monomer for rapid magnetic removal of Co (II) ions from aqueous solutions. Polym Adv Technol. 2018;29:1988–2001.
- [13] Rezaei M, Amani K, Darvishi K. One-pot green catalytic synthesis of primary amides in aqueous medium by Cu II-immobilized silica-based magnetic retrievable nanocatalyst. Catal Commun. 2017;91:38–42.
- [14] Rezaei M, Azizi K, Amani K. Copper-birhodanine complex immobilized on Fe₃O₄ nanoparticles: DFT studies and heterogeneous catalytic applications in the synthesis of propargylamines in aqueous medium. Appl Organomet Chem. 2018;32:e4120.
- [15] Hardej D, Ashby Jr CR, Khadtare NS, et al. The synthesis of phenylalanine-derived C5substituted rhodanines and their activity against selected methicillin-resistant *Staphylococcus aureus* (MRSA) strains. Eur J Med Chem. 2010;45:5827–5832.
- [16] Talele TT, Arora P, Kulkarni SS, et al. Structure-based virtual screening, synthesis and SAR of novel inhibitors of hepatitis C virus NS5B polymerase. Bioorg Med Chem. 2010;18: 4630–4638.
- [17] Song Y, Connor DT, Doubleday R, et al. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series. J Med Chem. 1999;42:1151–1160.
- [18] Safonov IG, Heerding DA, Keenan RM, et al. New benzimidazoles as thrombopoietin receptor agonists. Bioorg Med Chem Lett. 2006;16:1212–1216.
- [19] Powers JP, Piper DE, Li Y, et al. SAR and mode of action of novel non-nucleoside inhibitors of hepatitis C NS5b RNA polymerase. J Med Chem. 2006;49:1034–1046.
- [20] Khodari A, Nielsen J. Synthesis of 3-substituted 5-arylidene-1-methyl-2-thiohydantoins under microwave irradiation. Heterocycles. 2002;57:1017–1032.

12 🕒 L. SABAHI-AGABAGER AND F. NASIRI

- [21] Li H-q, Yang J, Ma S, et al. Structure-based design of rhodanine-based acylsulfonamide derivatives as antagonists of the anti-apoptotic Bcl-2 protein. Bioorg Med Chem. 2012;20:4194–4200.
- [22] Bourahla K, Derdour A, Rahmouni M, et al. A practical access to novel 2-amino-5-arylidene-1, 3-thiazol-4 (5H)-ones via sulfur/nitrogen displacement under solvent-free microwave irradiation. Tetrahedron Lett. 2007;48:5785–5789.
- [23] Üngören ŞH, Albayrak S, Guenay A, et al. A new method for the preparation of 5-acylidene and 5-imino substituted rhodanine derivatives and their antioxidant and antimicrobial activities. Tetrahedron. 2015;71:4312–4323.
- [24] Chauhan K, Sharma M, Saxena J, et al. Synthesis and biological evaluation of a new class of 4-aminoquinoline-rhodanine hybrid as potent anti-infective agents. Eur J Med Chem. 2013;62:693-704.
- [25] Werner MM, Patel BA, Talele TT, et al. Dual inhibition of *Staphylococcus aureus* DNA gyrase and topoisomerase IV activity by phenylalanine-derived (Z)-5-arylmethylidene rhodanines. Bioorg Med Chem. 2015;23:6125–6137.
- [26] Li C, Liu J-C, Li Y-R, et al. Synthesis and antimicrobial evaluation of 5-aryl-1, 2, 4-triazole-3thione derivatives containing a rhodanine moiety. Bioorg Med Chem Lett. 2015;25:3052–3056.
- [27] Azizi N, Hasani M, Khajeh M, et al. A straightforward and sustainable one-pot, fourcomponent synthesis of rhodanine derivatives. Tetrahedron Lett. 2015;56:1189–1192.
- [28] Mermer A, Demirbas N, Colak A, et al. One-pot, four-component green synthesis, carbonic anhydrase II inhibition and docking studies of 5-arylide nerhodanines. ChemistrySelect. 2018;3:12234–12242.
- [29] Singh SJ, Ahmad S, Chauhan S. 1-Butyl-3-methyl imidazolium acetate catalyzed synthesis of N-substituted-5-arylidene-rhodanines. J Heterocycl Chem. 2014;51:E129–E139.
- [30] Nasiri F, Nazari P. One-pot solvent-free three-component reaction between primary amines, carbon disulfide, and 5-alkylidene rhodanines: a convenient synthesis of asymmetric birhodanines. Mol Divers. 2018;22:601–608.
- [31] Nasiri F, Zolali A, Asadbegi S. Solvent-free one-pot synthesis of 2, 2'-dithioxo-[5, 5'] bithiazolidinylidene-4, 4'-diones. J Heterocycl Chem. 2016;53:989–992.
- [32] Nasiri F, Zolali A, Ahmadiazar M. A convenient solvent-free and one-pot synthesis of 4hydroxythiazolidine-2-thiones. J Sulfur Chem. 2014;35:412–417.
- [33] Nasiri F, Zolali A, Kadkhoda J. Stereoselective solvent-free synthesis of 4-hydroxy-1, 3thiazinane-2-thiones. J Heterocycl Chem. 2016;53:937–940.
- [34] Alizadeh A, Zohreh N. A novel multicomponent method for the synthesis of 2-thioxo-1, 3thiazolidin-4-ones. Synlett 2009;2009:2146–2148.
- [35] Lapina I, Pevzner L, Potekhin A. Reactions of alkyl (halomethyl) furancarboxylates with hexamethylenetetramine. Russ J Gen Chem. 2006;76:1304–1309.
- [36] Rinkes I. J. 5-Methylfurfural. Org Synth. 1934;14:62-63.
- [37] Rajmohan R, Gayathri S, Vairaprakash P. Facile synthesis of 5-hydroxymethylfurfural: a sustainable raw material for the synthesis of key intermediates toward 21, 23-dioxaporphyrins. RSC Adv. 2015;5:100401-100407.